特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
941393

肝臓がん治療薬市場 - 分析、シェア、動向、規模、予測:2020年~2026年

Liver Cancer Drugs Market, By By Therapeutic Class, By Type, and By Geography - Analysis, Share, Trends, Size, & Forecast From 2020 - 2026

出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 165 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
肝臓がん治療薬市場 - 分析、シェア、動向、規模、予測:2020年~2026年
出版日: 2020年06月01日
発行: AnalystView Market Insights
ページ情報: 英文 165 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

肝臓がん治療薬市場は、2019年までに6億3010万米ドルに達し、2020年~2026年の予測期間中のCAGRで、16.4%の成長が予測されています。

当レポートでは、世界の肝臓がん治療薬市場について調査分析し、市場概要、市場力学、セグメント別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 肝臓がん治療薬市場の概要

  • 調査範囲
  • 前提条件と調査手法

第2章 エグゼクティブサマリー

第3章 肝臓がん治療薬の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 肝臓がん治療薬業界分析

  • ポーターのファイブフォース分析
  • マーケティング戦略分析
  • 成長見通しマッピング
  • 規制の枠組み分析
  • COVID-19の影響分析

第5章 肝臓がん治療薬市場情勢

  • 市場シェア分析
  • 主要イノベーター
  • 内訳データ:主要メーカー別

第6章 肝臓がん治療薬市場:薬効分類別

  • 概要
  • 標的療法
  • 免疫療法
  • その他

第7章 肝臓がん治療薬市場:タイプ別

  • 概要
  • 肝芽腫
  • 肝細胞がん
  • 胆管がん
  • その他

第8章 肝臓がん治療薬市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 主要ベンダー分析

  • Merck
  • Bristol-Myers Squibb
  • Bayer
  • Eisai
  • Exelixis
  • Onyx Pharmaceuticals Inc
  • Alnylam Pharmaceuticals, Inc
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd.

第10章 アナリストの見解

第11章 付録

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Liver Cancer Drugs market: Therapeutic Class Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Class
  • TABLE Global Liver Cancer Drugs market, by Therapeutic Class 2015-2026 (USD Million)
  • TABLE Liver Cancer Drugs market: Type Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Liver Cancer Drugs market, by Type 2015-2026 (USD Million)
  • TABLE Liver Cancer Drugs market: Regional snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Liver Cancer Drugs market, by Region 2015-2026 (USD Million)
  • TABLE North America Liver Cancer Drugs market, by Country, 2015-2026 (USD Million)
  • TABLE North America Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE North America Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)
  • TABLE Europe Liver Cancer Drugs market, by country, 2015-2026 (USD Million)
  • TABLE Europe Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Europe Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)
  • TABLE Asia Pacific Liver Cancer Drugs market, by country, 2015-2026 (USD Million)
  • TABLE Asia Pacific Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Asia Pacific Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)
  • TABLE Latin America Liver Cancer Drugs market, by country, 2015-2026 (USD Million)
  • TABLE Latin America Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Latin America Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Liver Cancer Drugs market, by country, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Liver Cancer Drugs market, by Therapeutic Class, 2015-2026 (USD Million)
  • TABLE Middle East and Africa Liver Cancer Drugs market, by Type, 2015-2026 (USD Million)

List of Figures

  • FIGURE Liver Cancer Drugs market segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2018
  • FIGURE Therapeutic Class segment market share analysis, 2019 & 2026
  • FIGURE Therapeutic Class segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Targeted Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Immunotherapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Type segment market share analysis, 2019 & 2026
  • FIGURE Type segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Hepatoblastoma segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Hepatocellular Carcinoma segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Cholangio Carcinoma segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Regional segment market share analysis, 2019 & 2026
  • FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE North America Liver Cancer Drugs market share and leading players, 2018
  • FIGURE Europe Liver Cancer Drugs market share and leading players, 2018
  • FIGURE Asia Pacific Liver Cancer Drugs market share and leading players, 2018
  • FIGURE Latin America Liver Cancer Drugs market share and leading players, 2018
  • FIGURE Middle East and Africa Liver Cancer Drugs market share and leading players, 2018
  • FIGURE North America Liver Cancer Drugs market share analysis by country, 2018
  • FIGURE U.S. Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Canada Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Europe Liver Cancer Drugs market share analysis by country, 2018
  • FIGURE Germany Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Spain Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Italy Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE UK Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE France Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of the Europe Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Asia Pacific Liver Cancer Drugs market share analysis by country, 2018
  • FIGURE India Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE China Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Japan Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE South Korea Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Singapore Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of APAC Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latin America Liver Cancer Drugs market share analysis by country, 2018
  • FIGURE Brazil Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Mexico Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Argentina Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rest of LATAM Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Middle East and Africa Liver Cancer Drugs market share analysis by country, 2018
  • FIGURE Saudi Arabia Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE United Arab Emirates Liver Cancer Drugs market size, forecast and trend analysis, 2015 to 2026 (USD Million)
目次

REPORT HIGHLIGHT

Liver cancer drugs market was valued at USD 630.1 million by 2019, growing with 16.4% CAGR during the forecast period, 2020-2026

Market Dynamics

Liver cancer is estimated to be the fifth most prevalent cancer and accounts for about 9.0% of all cancer deaths across the globe. In 2012, around 782,451 novel cases of liver cancer were diagnosed, of which 745,533 deaths were reported due to the life-threatening disease. Primary liver cancer remains a significant public health issue owing to poor survival rate and its extremely aggressive nature. Hepatocellular carcinoma is one of the most common types of liver cancer that begins in the hepatocyte, which is the main type of liver cell.

The growing prevalence of liver cancer, government initiatives to increase cancer awareness, and increasing investments in R&D activities to develop novel therapies are the major factors driving the growth of global liver cancer drugs market. In addition, the large amount of the population is exposed to certain risk factors contributing to liver cancer owing to the growing adoption of unhealthy lifestyle by people. Also, heavy consumption of alcohol and tobacco smoking are the encouraging factors for liver cancer. Thus, the above-mentioned factors will propel the market growth during the forecast period. The estimations by the American Cancer Society states that there would be around 42,810 novel cases of liver cancer in the U.S. by the end of 2020. Moreover, the rising demand for therapeutic drugs for the treatment of liver cancer is likely to create lucrative opportunities in the global industry. However, a dearth in the number of donors and the diagnosis of disease in the advanced stage with no feasibility of transplantation or surgery is predicted to restrict the market growth in the coming future.

Therapeutic Class Takeaway

The immunotherapy segment is anticipated to generate the majority of share in the global market owing to increasing R&D investments and the launch of novel drugs for treating liver cancer. If patients have an adequate reserve for hepatic function, the optimal treatment for HCC is a partial surgical resection. The resection of cirrhotic livers can grow the risk of liver failure which is a fatal complication. However, the resection rates have improved hugely after resection over the past few decades. On the other hand, the relapse rates are very high for after surgical resection. In the treatment of HCC, most of the systemic drugs have minimal efficacy, and thus R&D is primarily focused on hepatocarcinogenesis.

The HCC or hepatocellular carcinoma is the most common form of liver cancer. HCC mostly occurs in people who are suffering from chronic liver diseases such as cirrhosis. It is also one of the major causes of cancer-related deaths all across the globe. It is observed that the African and Asian countries have higher prevalence rates of hepatocellular carcinoma as compared to the developed economies. This is majorly owing to the disparity in the main risk factors causing HCC such as hepatitis B and C virus infection in these regions. With the rise in the occurrence of hepatocellular carcinoma, there is projected to be a huge demand for liver cancer drugs. Hence, the growing prevalence of cancer and the rise in unmet medical needs are the significant factors driving the segmental market growth of HCC during the period of forecast.

REGIONAL TAKEAWAY

Presently, the North America region is dominating the market owing to the growing geriatric population and the presence of well-established healthcare infrastructure in this region. On the other hand, the Asia Pacific market for liver cancer drugs will grow at a notable rate owing to the higher prevalence rates of HCC than other regions in the world.

Key vendors of the market include:

  • Merck
  • Bristol-Myers Squibb
  • Bayer
  • Eisai
  • Exelixis
  • Ono Pharmaceutical
  • Onyx Pharmaceuticals Inc
  • Alnylam Pharmaceuticals, Inc
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd.

The market size and forecast for each segment and sub-segments has been considered as below:

  • Historical Year - 2015 to 2018
  • Base Year - 2019
  • Estimated Year - 2020
  • Projected Year - 2026

TARGET AUDIENCE

  • Traders, Distributors, and Suppliers
  • Manufacturers
  • Government and Regional Agencies
  • Research Organizations
  • Consultants
  • Distributors

Scope of the Report

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL LIVER CANCER DRUGS MARKET, BY THERAPEUTIC CLASS

  • Immunotherapy
  • Targeted Therapy

GLOBAL LIVER CANCER DRUGS MARKET, BY TYPE

  • Hepatoblastoma
  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • Others

GLOBAL LIVER CANCER DRUGS MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Singapore
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Rest of MEA

TABLE OF CONTENT

1. LIVER CANCER DRUGS MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Therapeutic Class
    • 2.1.2. Market Snippet by Type
    • 2.1.3. Market Snippet by Region
  • 2.2. Competitive Insights

3. LIVER CANCER DRUGS KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. LIVER CANCER DRUGS INDUSTRY STUDY

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis
  • 4.5. COVID-19 Impact Analysis
    • 4.5.1. Pre-COVID-19 Impact Analysis
    • 4.5.2. Post-COVID-19 Impact Analysis

5. LIVER CANCER DRUGS MARKET LANDSCAPE

  • 5.1. Market Share Analysis
  • 5.2. Key Innovators
  • 5.3. Breakdown Data, by Key manufacturer
    • 5.3.1. Established Player Analysis
    • 5.3.2. Emerging Player Analysis

6. LIVER CANCER DRUGS MARKET - BY THERAPEUTIC CLASS

  • 6.1. Overview
    • 6.1.1. Segment Share Analysis, By Therapeutic Class, 2019 & 2026 (%)
  • 6.2. Targeted Therapy
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.3. Immunotherapy
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.4. Others
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

7. LIVER CANCER DRUGS MARKET - BY TYPE

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2019 & 2026 (%)
  • 7.2. Hepatoblastoma
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.3. Hepatocellular Carcinoma
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.4. Cholangio Carcinoma
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.5. Others
    • 7.5.1. Overview
    • 7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

8. LIVER CANCER DRUGS MARKET- BY GEOGRAPHY

  • 8.1. Introduction
    • 8.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
  • 8.2. North America
    • 8.2.1. Overview
    • 8.2.2. Key Manufacturers in North America
    • 8.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.2.4. North America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.2.5. North America Market Size and Forecast, By Type, 2015 - 2026 (US$ Million)
    • 8.2.6. U.S.
      • 8.2.6.1. Overview
      • 8.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.2.7. Canada
      • 8.2.7.1. Overview
      • 8.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.3. Europe
    • 8.3.1. Overview
    • 8.3.2. Key Manufacturers in Europe
    • 8.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.3.4. Europe Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.3.5. Europe Market Size and Forecast, By Type, 2015 - 2026 (US$ Million)
    • 8.3.6. Germany
      • 8.3.6.1. Overview
      • 8.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.7. Italy
      • 8.3.7.1. Overview
      • 8.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.8. United Kingdom
      • 8.3.8.1. Overview
      • 8.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.9. France
      • 8.3.9.1. Overview
      • 8.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.3.10. Rest of Europe
      • 8.3.10.1. Overview
      • 8.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.4. Asia Pacific (APAC)
    • 8.4.1. Overview
    • 8.4.2. Key Manufacturers in Asia Pacific
    • 8.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.4.4. Asia Pacific Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.4.5. Asia Pacific Market Size and Forecast, By Type, 2015 - 2026 (US$ Million)
    • 8.4.6. India
      • 8.4.6.1. Overview
      • 8.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.7. China
      • 8.4.7.1. Overview
      • 8.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.8. Japan
      • 8.4.8.1. Overview
      • 8.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.9. South Korea
      • 8.4.9.1. Overview
      • 8.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.4.10. Rest of APAC
      • 8.4.10.1. Overview
      • 8.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.5. Latin America
    • 8.5.1. Overview
    • 8.5.2. Key Manufacturers in Latin America
    • 8.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.5.4. Latin America Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.5.5. Latin America Market Size and Forecast, By Type, 2015 - 2026 (US$ Million)
    • 8.5.6. Brazil
      • 8.5.6.1. Overview
      • 8.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.7. Mexico
      • 8.5.7.1. Overview
      • 8.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.8. Argentina
      • 8.5.8.1. Overview
      • 8.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.5.9. Rest of LATAM
      • 8.5.9.1. Overview
      • 8.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Overview
    • 8.6.2. Key Manufacturers in Middle East and Africa
    • 8.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 8.6.4. Middle East and Africa Market Size and Forecast, By Therapeutic Class, 2015 - 2026 (US$ Million)
    • 8.6.5. Middle East and Africa Market Size and Forecast, By Type, 2015 - 2026 (US$ Million)
    • 8.6.6. Saudi Arabia
      • 8.6.6.1. Overview
      • 8.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 8.6.7. United Arab Emirates
      • 8.6.7.1. Overview
      • 8.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

9. KEY VENDOR ANALYSIS

  • 9.1. Merck
    • 9.1.1. Company Snapshot
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Strategic Initiatives
  • 9.2. Bristol-Myers Squibb
  • 9.3. Bayer
  • 9.4. Eisai
  • 9.5. Exelixis
  • 9.6. Onyx Pharmaceuticals Inc
  • 9.7. Alnylam Pharmaceuticals, Inc
  • 9.8. Pfizer Inc
  • 9.9. F. Hoffmann-La Roche Ltd.

10. 360 DEGREE ANALYSTVIEW

11. APPENDIX

  • 11.1. Research Methodology
  • 11.2. References
  • 11.3. Abbreviations
  • 11.4. Disclaimer
  • 11.5. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.